|
US2017056468A1
|
|
Treatment of resistant lesions
|
|
US2016160214A1
|
|
Formulations comprising antisense nucleotides to connexins
|
|
AU2015202329A1
|
|
Impaired wound healing compositions and treatments
|
|
EP3116996A2
|
|
Treatment of resistant lesions
|
|
AU2015201309A1
|
|
Treatment of fibrotic conditions
|
|
AU2015201305A1
|
|
Treatment of fibrotic conditions
|
|
EP3110455A2
|
|
Treatment of resistant lesions
|
|
AU2015200114A1
|
|
Improved medical devices
|
|
AU2014204482A1
|
|
Anticonnexin polynucleotides as impaired wound healing compositions
|
|
CN104736709A
|
|
Compositions and treatments based on cadherin modulation
|
|
US2014275209A1
|
|
Wound healing compositions and treatments
|
|
US2014274872A1
|
|
Compositions and treatments based on cadherin modulation
|
|
CN102099475A
|
|
Treatment of pain with gap junction modulation compounds
|
|
WO2009097077A2
|
|
Wound healing compositions and treatments
|
|
EP2234656A2
|
|
Improved medical devices
|
|
WO2009085271A2
|
|
Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
|
|
CA2710387A1
|
|
Treatment of fibrotic conditions
|
|
AU2008343839A1
|
|
Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
|
|
CA2710227A1
|
|
Treatment of surgical adhesions
|
|
EP2252690A2
|
|
Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
|
